# Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

> **NCT07670858** · PHASE1 · RECRUITING · sponsor: **Feldan Therapeutics** · enrollment: 48 (estimated)

## Conditions studied

- Nodular Basal Cell Carcinoma

## Interventions

- **DRUG:** Intralesional FLD-103

## Key facts

- **NCT ID:** NCT07670858
- **Lead sponsor:** Feldan Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670858, "Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*